MiNK Therapeutics (INKT) Debt Ratio (2020 - 2024)

MiNK Therapeutics (INKT) posted Debt Ratio of 0.86 for Q4 2024, up 37.66% sequentially from 0.63 in Q3 2024.

MiNK Therapeutics (INKT) Debt Ratio (2020 - 2024) Analysis & Trends

MiNK Therapeutics has reported Debt Ratio for 5 years, with the latest figure at 0.86 in Q4 2024.

Quarterly Debt Ratio changed N/A year-over-year to 0.86 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.86 (changed N/A YoY) and the FY2024 annual result came in at 0.86, changed N/A from the prior year.
Debt Ratio advanced to 0.86 in Q4 2024 per INKT's latest filing, from 0.63 in the prior quarter.
Over five years, Debt Ratio peaked at 1.23 in Q3 2021 and troughed at 0.15 in Q4 2021.
A 5-year average of 0.54 and a median of 0.51 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2021 and 2023: Debt Ratio tumbled 80.94% in 2021, then surged 200.82% in 2023.
Over 5 years, Debt Ratio stood at 0.78 in 2020, then sank by 80.94% to 0.15 in 2021, then surged by 186.28% to 0.42 in 2022, then surged by 38.54% to 0.59 in 2023, then surged by 46.91% to 0.86 in 2024.
According to Business Quant data, Debt Ratio over the past three periods registered 0.86, 0.63, and 0.43 for Q4 2024, Q3 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	0.05
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	-
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	-
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	0.03
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.47
10	MiNK Therapeutics	60.53 Mn	60.53 Mn	-	-

Download Data